Holen Sie sich die Stockscreener-App
50.64
1.71%
-0.88
Handel nachbörslich:
50.64
Schlusskurs vom Vortag:
$51.52
Offen:
$50.99
24-Stunden-Volumen:
4.84M
Relative Volume:
1.16
Marktkapitalisierung:
$101.54B
Einnahmen:
$43.93B
Nettoeinkommen (Verlust:
$8.53B
KGV:
13.24
EPS:
3.824
Netto-Cashflow:
$5.74B
1W Leistung:
+2.70%
1M Leistung:
+0.46%
6M Leistung:
+4.48%
1J Leistung:
+22.91%
1-Tages-Spanne:
$50.46
$51.38
1-Wochen-Bereich:
$48.57
$51.97
52-Wochen-Spanne:
$35.45
$61.70
Gsk Plc Adr Stock (GSK) Company Profile
Compare GSK vs LLY, JNJ, ABBV, MRK, AZN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
50.64 | 103.31B | 43.93B | 8.53B | 5.74B | 3.824 |
LLY
Lilly Eli Co
|
1,149.15 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.16 | 560.33B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
223.07 | 401.47B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
119.52 | 298.33B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
181.55 | 288.38B | 60.48B | 10.40B | 8.05B | 3.3297 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2026-01-06 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-11-25 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-03 | Herabstufung | Berenberg | Buy → Hold |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-07-08 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-03-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2024-01-03 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-03-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Fortgesetzt | Goldman | Buy |
| 2023-01-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Herabstufung | UBS | Neutral → Sell |
| 2022-09-15 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Fortgesetzt | Citigroup | Neutral |
| 2022-02-11 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Hold |
| 2020-11-02 | Hochstufung | Liberum | Hold → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-02-12 | Herabstufung | Shore Capital | Hold → Sell |
| 2020-01-16 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-21 | Hochstufung | UBS | Neutral → Buy |
| 2019-10-11 | Hochstufung | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Fortgesetzt | Citigroup | Neutral |
| 2019-09-03 | Hochstufung | Societe Generale | Sell → Buy |
| 2019-08-13 | Fortgesetzt | JP Morgan | Neutral |
| 2019-06-17 | Fortgesetzt | Morgan Stanley | Underweight |
| 2019-03-08 | Herabstufung | Shore Capital | Buy → Hold |
| 2019-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-14 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-08-30 | Herabstufung | Liberum | Buy → Hold |
| 2018-04-04 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Hochstufung | Kepler | Reduce → Hold |
Alle ansehen
Gsk Plc Adr Aktie (GSK) Neueste Nachrichten
Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy? - The Motley Fool
Why is Glaxo (GSK) down 2.1% since last earnings report? - MSN
GSK Bets on Specialty Medicines to Drive Long-Term Revenue Growth - TradingView
symbol__ Stock Quote Price and Forecast - CNN
GSK Stock Price, Quote & Chart | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
GSK plc (ADR) stock (GB0009252882): ADR treads water around mid-USD 50s as London shares retreat on - AD HOC NEWS
GSK plc (ADR) stock (GB0009252882): ADR holds steady as investors await next catalysts after recent - AD HOC NEWS
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Revenue Breakdown – BCBA:GSK.CI - TradingView
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Earnings and Revenue – BCBA:GSK.CI - TradingView
GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs Balance Sheet – BCBA:GSK.CI - TradingView
GSK PLC-SPON ADR (NYSE:GSK) Passes Quality-Focused Caviar Cruise Stock Screener with Strong Profitability and Cash Flow - ChartMill
GSK plc stock (GB0009252882): buyback activity and Q1 update keep focus on vaccines and specialty me - AD HOC NEWS
GSK PLC (GSK) Stock Price, Trades & News - GuruFocus
GSK plc stock (GB0009252882): asthma drug progress and Q1 update draw investor focus - AD HOC NEWS
GSK plc stock (GB0009252882): Q1 2026 beat, raised outlook and steady dividend attract fresh attenti - AD HOC NEWS
GSK plc stock (GB0009252882): Fresh 13F filing and annual report keep big pharma in focus - AD HOC NEWS
The Best Healthcare Stocks to Buy - Morningstar
GSK plc (GSK) Stock Price, News, Quote & History - Yahoo Finance
GSK plc stock (GB0009252882): Mixed signals from recent earnings and pipeline updates - AD HOC NEWS
129,513 Shares in GSK PLC Sponsored ADR $GSK Acquired by PFA Pension Forsikringsaktieselskab - MarketBeat
Major holder in GSK (NYSE: GSK) reports 4.93% of voting rights - Stock Titan
GSK PLC Sponsored ADR Announces Quarterly Dividend of $0.44 (NYSE:GSK) - MarketBeat
Vaccine Star Shingrix Lifts GSK, But Weak Segments Raise Eyebrows - Sahm
Elizabeth Warren Calls Trump's '600%' Drug Price Claim Mathematically Impossible: 'His Promise Is As Empty As…' - Sahm
GSK Q1 Earnings Beat Estimates, Specialty Medicines Drive Sales Growth - TradingView
Finanzdaten der Gsk Plc Adr-Aktie (GSK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.61%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):